Exagen Inc. (XGN)

Market Cap	45.53M
Revenue (ttm)	44.30M
Net Income (ttm)	-37.81M
Shares Out	16.26M
EPS (ttm)	-1.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,509
Open	2.80
Previous Close	2.71
Day's Range	2.79 - 2.98
52-Week Range	2.65 - 14.85
Beta	1.03
Analysts	Buy
Price Target	12.50 (+346.4%)
Earnings Date	Nov 8, 2022

About XGN

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue dis...

• Industry: Health Care Providers & Services
• IPO Date: Sep 19, 2019
• CEO: Fortunato Rocca
• Employees: 219
• Stock Exchange: NASDAQ
• Ticker Symbol: XGN

Full Company Profile

Financial Performance

In 2021, Exagen's revenue was $48.30 million, an increase of 15.07% compared to the previous year's $41.98 million. Losses were -$26.85 million, 60.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for XGN stock is "Buy." The 12-month stock price forecast is 12.5, which is an increase of 346.43% from the latest price.

Price Target

$12.5

(346.43% upside)

Analyst Consensus: Buy

Stock Forecasts